Cardiovascular complications for men with prostate cancer are predominantly related to the unique situation that these patients fall into when their testosterone decreases due to treatment with androgen deprivation therapy. This is a population that’s already vulnerable, an aging male. Joining Alicia Morgans, MD, MPH, is Vivek Narayan, MD, MS to highlight a paper on Cardiovascular Toxicities of Therapy for Genitourinary Malignancies
and how these toxicities really relate to prostate cancer treatment. Dr. Narayan emphasizes the key to managing CV toxicities is awareness. How do we best identify and risk-stratify these patients so that as we develop new tools to mitigate that risk?
Vivek K. Narayan, MD, MS, Medical Oncologist, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.